Vimarsana
Biggest News Aggregation in the World

Liquidia Techs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Liquidia Techs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Liquidia Techs Today - Breaking & Trending Today

Eye on IPRs, February 2024: Supreme Court Passes on Fintiv Challenge, Parallel IPR/District Court Litigation, First Precedential Review of the Year | Erise IP - Vimarsana News

Eye on IPRs, February 2024: Supreme Court Passes on Fintiv Challenge, Parallel IPR/District Court Litigation, First Precedential Review of the Year | Erise IP

Published: February 28, 2024

Every month, Erise’s patent attorneys review the latest inter partes review cases and news to bring you the stories that you should know about: SCOTUS Won’t Hear...

Source: jdsupra.com
Related Topics:
United StatesKathi VidalUnited Therapeutics CorpEdwards Life SciencesUs Supreme CourtDistrict Court LitigationTrademark Office Patent TrialSupreme CourtHear ChallengeBloomberg LawTrademark OfficePatent TrialAppeal BoardAmerica Invents ActDistrict CourtLiquidia TechsTherapeutics CorpFederal CircuitFirst Precedential DecisionAbbott DiabetesWhether Abbott
PTAB Invalidates United Therapeutics Patent Relating To The Hypertension Drug - Tyvaso® - Patent - Vimarsana News

PTAB Invalidates United Therapeutics Patent Relating To The Hypertension Drug - Tyvaso® - Patent

Published: September 22, 2022

In Liquidia Techs., Inc. v. United Therapeutics Corp.,[1] the Patent Trial and Appeal Board ("the PTAB") held all challenged claims of U.S. Patent No. 10,716,793 ("the '793 patent") unpatentable under 35 U.S.C. § 103.

Source: mondaq.com
Related Topics:
Liquidia Techs IncFox Factory IncLiquidia TechsPatent TrialAppeal BoardUnited TherapeuticLoreal United StatesPtab Invalidates United Therapeutics Patent Relating To The Hypertension Drug Tyvaso Xae Intellectual Property